This is because it targets three different receptors and hormones GLP-1, glucagon and GIP (1)
Both drugs may vary in price depending on factors like location
According to estimates published by researchers at the Vanderbilt University School of Medicine and the University of Chicago Department of Medicine in the New England Journal of Medicine in March, if 10% of Medicare beneficiaries with obesity would receive coverage for Wegovy, it would cost Medicare Part D around $26.8 billion per year
Our team is here to help guide you through every step of the process.
Postmarketing surveillance and observational studies have reported cases of pancreatitis in patients receiving GLP-1 receptor agonists, although a causal relationship remains debated and confounded by underlying disease risk factors (Drucker, 2018)
You will be required to complete a consultation online, which is checked by a pharmacist